Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Angiotensin-converting enzyme

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1991

2

1996

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Hypertension

5

Heart failure post myocardial infarction

3

Congestive heart failure

2

Myocardial infarction

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

Preventing

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sanofi-Aventis

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

DRUG BANK

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

2

LIPID MODIFYING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ACE INHIBITORS, COMBINATIONS

2

ACE INHIBITORS, PLAIN

2

LIPID MODIFYING AGENTS, COMBINATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

ACE inhibitors and calcium channel blockers

2

ACE inhibitors, plain

2

ACE inhibitors and diuretics

1

ACE inhibitors, other combinations

1

HMG CoA reductase inhibitors, other combinations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TRANDOLAPRILAT

RR6866VL0O

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Heart failure post myocardial infarction

Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the e...

nzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. Trandolapril is marketed by Abbott Laboratories under the brand name Mavik.

RAMIPRILAT

6N5U4QFC3G

Export Data
Search for Structure

Status:

US Approved Rx (2008)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Congestive heart failure

Myocardial infarction

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of...

ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

TRANDOLAPRIL

1T0N3G9CRC

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Heart failure post myocardial infarction

Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the e...

nzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. Trandolapril is marketed by Abbott Laboratories under the brand name Mavik.

TRANDOLAPRIL HYDROCHLORIDE

3EY8XK2J4T

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Heart failure post myocardial infarction

Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the e...

nzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. Trandolapril is marketed by Abbott Laboratories under the brand name Mavik.

RAMIPRIL

L35JN3I7SJ

Export Data
Search for Structure

Status:

US Approved Rx (2008)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Congestive heart failure

Myocardial infarction

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of...

ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1